DCF Advisers LLC Takes Position in Incyte Corporation $INCY

DCF Advisers LLC purchased a new stake in Incyte Corporation (NASDAQ:INCY – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 41,500 shares of the biopharmaceutical company’s stock, valued at approximately $4,704,000. Incyte accounts for approximately 0.8% of DCF Advisers LLC’s investment portfolio, making the stock its 20th biggest position.

Other institutional investors have also recently bought and sold shares of the company. Elyxium Wealth LLC purchased a new stake in Incyte during the fourth quarter valued at about $28,000. Smithfield Trust Co increased its position in shares of Incyte by 135.0% in the fourth quarter. Smithfield Trust Co now owns 282 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 162 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Incyte in the fourth quarter worth approximately $35,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Incyte during the fourth quarter valued at approximately $35,000. Finally, Leonteq Securities AG acquired a new stake in shares of Incyte during the fourth quarter valued at approximately $35,000. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Get Incyte alerts:

Incyte Stock Up 4.0%

Shares of NASDAQ:INCY opened at $128.47 on Thursday. The firm has a fifty day moving average of $115.40 and a two-hundred day moving average of $103.81. The firm has a market capitalization of $26.04 billion, a P/E ratio of 16.37, a price-to-earnings-growth ratio of 3.91 and a beta of 0.76. Incyte Corporation has a 12-month low of $81.09 and a 12-month high of $132.60.

Incyte (NASDAQ:INCY – Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share for the quarter, topping analysts’ consensus estimates of $2.15 by $0.94. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The business had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the prior year, the business posted $1.57 earnings per share. Incyte’s revenue for the quarter was up 37.7% compared to the same quarter last year. Equities research analysts expect that Incyte Corporation will post 2.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Incyte news, EVP Patrick A. Mayes sold 41,899 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $119.46, for a total value of $5,005,254.54. Following the transaction, the executive vice president owned 61,441 shares in the company, valued at $7,339,741.86. The trade was a 40.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Guggenheim raised their price objective on shares of Incyte from $136.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Morgan Stanley set a $119.00 target price on shares of Incyte in a research note on Wednesday, July 29th. Citigroup restated a “buy” rating on shares of Incyte in a report on Monday, August 3rd. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $104.00 target price on shares of Incyte in a research report on Thursday, August 13th. Finally, Weiss Ratings upgraded Incyte from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, July 29th. Ten analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat.com, Incyte presently has a consensus rating of “Hold” and a consensus price target of $121.65.

View Our Latest Stock Report on INCY

Incyte Company Profile

(Free Report)

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.

Further Reading

• Five stocks we like better than Incyte
• Bloom Energy’s AI Surge Meets a Valuation Reality Check
• Target Is Winning Shoppers Back—Can the Rally Reach $180?
• IonQ’s Space Contract Points to a New Frontier for Quantum Investors
• Is Apple’s AI Strategy Smarter Than Skeptics Think?

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.